In a new article published in the Journal of the National Cancer Institute, Moffitt Cancer Center researchers report that patients treated with immune checkpoint inhibitors have a higher self-reported quality of life than patients treated with other types of therapy.
An expert review by an international group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe COVID is so high that booster doses for the general population are not appropriate at this stage in the pandemic.
MD Anderson and SNIPR BIOME have announced a strategic collaboration to advance next-generation CRISPR-based microbiome therapies to reduce immune-related side effects in patients treated with immune checkpoint inhibitors.
A research team has identified a potential cause of long-lasting symptoms experienced by COVID-19 patients, often referred to as long-haulers. The findings were published in the journal, The Public Library of Science ONE (PLOS ONE).
The presence of special immune system defense molecules, called autoimmune antibodies, has been strongly tied to how poorly people fare when hospitalized with COVID-19, a new study shows.
The gut microbiome can impact us in a variety of different ways, from our metabolism to our mood. Now, NIBIB-funded researchers are investigating if a fiber-based gel can restore beneficial microbes in the gut to enhance the efficacy of immune checkpoint inhibitors, a type of cancer immunotherapy treatment, in mice.
As students head back to school this fall, sports medicine physicians with Loyola Medicine say the risk of COVID-19 exposure among student athletes is low. As the Delta variant of COVID-19 continues to spread across the U.S., Nathaniel Jones, MD, a sports medicine physician for Loyola Medicine, emphasizes the importance of getting vaccinated.
A new analysis by a team of physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) provides the first evidence that monoclonal antibodies were indeed underutilized in the first six months of FDA authorization.
Gene-based, single-dose AAVCOVID vaccine shown to offer disease protection in challenge study, and to elicit year-long immune response, according to new paper in Cell Host & Microbe.
A research team at the RIKEN Center for Emergent Matter Science (CEMS) in Japan has developed a diagnostic system that can rapidly and sensitively measure the amount of antibodies in the blood that can protect us from SARS-CoV-2, the virus that causes COVID-19.
In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters.
Wistar welcomes Amelia Escolano, Ph.D., and Nan Zhang, Ph.D., as assistant professors.
St. Jude Children’s Research Hospital scientists detail how inflammasomes act as integral components of mega-cell death complexes called PANoptosomes for host defense in live viral and bacterial infections.
Lab studies reveal protein HSP27’s role in blood vessel leakage, opening the possibility that therapeutically dialing its activity up or down might stabilize patients with sepsis.
A buildup of coronavirus in the lungs is likely behind the steep mortality rates seen in the pandemic, a new study finds. The results contrast with previous suspicions that simultaneous infections, such as bacterial pneumonia or overreaction of the body’s immune defense system, played major roles in heightened risk of death, the investigators say.
Nearly 90% of people taking immunosuppressants to treat autoimmune conditions produce an antibody response to COVID-19 vaccination, but the response is weaker than those generated by healthy people, according to a study by researchers at Washington University School of Medicine in St. Louis.
A new study shows that two months after the second Pfizer/Moderna vaccination, antibody response decreases 20% in adults with prior cases of COVID-19. The study also tests how well current vaccines resist emerging variants.
The breast milk of lactating mothers vaccinated against COVID-19 contains a significant supply of antibodies that may help protect nursing infants from the illness, according to new research from the University of Florida.
August 16, 2021 – Chulalongkorn Memorial Hospital, Thai Red Cross Society, and the Vaccine Research Center, Faculty of Medicine, Chulalongkorn University (CVRC) held a press conference on the progress of clinical trials for the Thai “ChulaCov19” mRNA vaccine. The clinical trial (Phase 1) was administered in healthy volunteers who are found to have good immunity after they have been vaccinated. The volunteers’ antibodies have been greatly boosted to prevent the original strain of the virus, and four other variants, namely Alpha, Beta, Gamma, and Delta. Manufacturing and preparation for registration to be used in an emergency are underway.
For those with backyard poultry, like chickens or ducks, a Texas A&M AgriLife expert encourages taking precautions against salmonella exposure as cases spike across the U.S.
A recent study led by an Iowa State University entomologist explores the different kinds of cells that make up mosquito immune systems. The research could shed light on how mosquitoes transmit malaria.
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments, and that fungi and bacteria have opposing effects on those responses.
Researchers at Washington University School of Medicine in St. Louis have identified an antibody that is highly protective against a broad range of viral variants.
A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
In a new article published in JNCI Cancer Spectrum, Moffitt Cancer Center researchers describe a prediction model they have created that includes information calculated from computed tomography images that can identify non-small cell lung cancer patients who are not likely to respond to immunotherapy.
The early COVID-19 vaccination campaign in the U.S. prevented nearly 140,000 deaths and 3 million cases of COVID-19 by the second week of May, according to a new study.
Expert Q&A: Do breakthrough cases mean we will soon need COVID boosters? The extremely contagious Delta variant continues to spread, prompting mask mandates, proof of vaccination, and other measures. Media invited to ask the experts about these and related topics.
T cells play an important role in the human immune system.
A new preclinical study led by researchers at the UCLA Jonsson Comprehensive Cancer Center suggests that treating people who have aggressive cancers, including melanoma, pancreatic and colorectal cancers, with immune checkpoint inhibitors, quickly followed with mutation-targeted therapy, can help overcome treatment resistance and help people live longer.
Regardless of COVID vaccination and past infection status, the real measurement of immunity for COVID is the quantity and quality of antibodies each person has. Researchers at Sinai Hospital in Baltimore are offering a glimpse at how widespread, rapid antibody testing may be conducted in the near future. This new testing methodology is 99.5% effective, is easy to use, works and looks like a home pregnancy test and yields results in 15-20 minutes allowing for mass testing, particularly amongst children, older adults, and other populations resistant to blood draws. The researchers say the testing may be the easiest, fastest way to determine if someone needs a booster shot.
Penn researchers have discovered that TSLP stimulates the immune system to release lipids through the skin’s oil-producing sebaceous glands in mice.
Researchers at Washington University School of Medicine in St. Louis have found that the delta variant of the virus that causes COVID-19 is largely unable to evade antibodies elicited by vaccination. The findings help explain why vaccinated people have been at low risk of getting seriously ill with COVID-19 despite a surge in cases caused by the delta variant.
Messenger-RNA (mRNA) vaccines against the coronavirus that causes COVID-19 provoke a swift and strong response by the immune system’s T cells—the heavy armor of the immune system—according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania.
The FDA and CDC have just approved and recommended an additional dose of mRNA COVID-19 vaccines for moderately and severely immunocompromised people. Who should get it?
Patients receiving in-hospital dialysis treatment for kidney disease produce a larger neutralising antibody response when given the Pfizer-BioNTech COVID-19 vaccine, compared to the Oxford-AstraZeneca vaccine, according to laboratory findings published today (Thursday) as a Correspondence in The Lancet.
Researchers in Moffitt Cancer Center’s Lung Cancer Center of Excellence believe a combination of checkpoint inhibitors with adoptive cell therapy could be the answer for non-small cell lung cancer patients. Results of their investigator-initiated phase 1 clinical trial evaluating the checkpoint inhibitor nivolumab in combination with tumor infiltrating lymphocyte (TIL) therapy was published today in Nature Medicine.
A two-arm molecule can effectively deplete cancer-protecting cells inside tumors, allowing the immune system to fight off tumors without becoming overactive. The finding, published online in Science Translational Medicine, could leaA two-arm molecule can effectively deplete cancer-protecting cells inside tumors, allowing the immune system to fight off tumors without becoming overactive. The finding, published online in Science Translational Medicine, could lead to new types of cancer immunotherapies.d to new types of cancer immunotherapies.
Mount Sinai researchers have found an important clue to a rare but serious aftereffect of COVID-19 in children, known as multisystem inflammatory syndrome in children or MIS-C.
妙佑医疗国际(Mayo Clinic) 的研究人员发现，与COVID-19（2019 冠状病毒病）相关的急性肾损伤类似于败血症引起的肾损伤，而且感染引发的免疫反应起着关键作用。
Os pesquisadores da Mayo Clinic descobriram que a lesão renal aguda associada com a COVID-19 é muito similar à lesão renal causada por sepse e que a resposta imunológica ativada pela doença exerce um papel central.
اكتشف باحثو مايو كلينك أن إصابة الكُلى الحادة المرتبطة بفيروس كورونا المستجد كوفيد-19 تماثل إصابة الكُلى الناتجة عن الإنتان، وتلعب الاستجابة المناعية الناجمة عن العدوى دورًا محوريًا فيها.
The levels of IgG antibodies against SARS-CoV-2 Spike protein remain stable, or even increase, seven months after infection, according to a follow-up study in a cohort of healthcare workers coordinated by the Barcelona Institute for Global Health (ISGlobal), an institution supported by “la Caixa” Foundation, in collaboration with the Hospital Clinic of Barcelona.
UC San Diego researchers report that solid organ transplant recipients who were vaccinated experienced an almost 80 percent reduction in the incidence of symptomatic COVID-19 compared to unvaccinated counterparts during the same time.
In an article in the New England Journal of Medicine, scientists from Fred Hutchinson Cancer Research Center, Johns Hopkins Bloomberg School of Medicine, the U.S. Military HIV Research Program and the Institute for Global Health and Infectious Diseases at the University of North Carolina urged increased attention to persistent COVID-19 infections in immunocompromised people.
A KAIST immunology research team found that a specific subtype of macrophages that originated from blood monocytes plays a key role in the hyper-inflammatory response in SARS-CoV-2 infected lungs, by performing single-cell RNA sequencing of bronchoalveolar lavage fluid cells.
The US Food and Drug Administration approved the drug anifrolumab (Saphnelo) on August 2, 2021 for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. Much of the groundwork for the development of this drug was done in laboratories at Hospital for Special Surgery (HSS) in the early 2000s.
Scientists at Children’s Hospital of Philadelphia (CHOP) have identified two proteins that could be used for a potential vaccine against nontypeable Haemophilus influenzae (NTHi). Working in a mouse model, the investigators found that administering two bacterial adhesive proteins that play a key role in helping the bacteria to latch on to respiratory cells and initiate respiratory tract infection stimulated protective immunity against diverse NTHi strains, highlighting the vaccine potential.
Johns Hopkins Medicine researchers, in collaboration with national and international researchers, have identified a genetic mutation in a small number of children with a rare type of inflammatory bowel disease. The discovery of the mutation, which weakens the activity of a protein linked to how the immune system fights viruses in the gut, may help researchers pinpoint the cause of more common bowel diseases, investigators say.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right